ArticleNature communications2022

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19.

Hengrui Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.